Results 151 to 160 of about 40,773 (330)

Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study

Cardiovascular Diabetology, 2020
Background Whether plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) levels is a predictor for cardiovascular outcomes has currently been controversial. No data is currently available regarding the relation of PCSK9 to cardiovascular metabolic
Jia Peng, Ming-Ming Liu, Jing-Lu Jin, Ye-Xuan Cao, Yuan-Lin Guo, Na-Qiong Wu, Cheng-Gang Zhu, Qian Dong, Jing Sun, Rui-Xia Xu, Jian-Jun Li   +10 more
doaj   +1 more source

Proprotein convertase subtilisin/kexin type 9 deficiency in extrahepatic tissues: emerging considerations

Frontiers in Pharmacology
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is primarily secreted by hepatocytes. PCSK9 is critical in liver low-density lipoprotein receptors (LDLRs) metabolism.
Fengyuan Lu, En Li, Xiaoyu Yang, Xiaoyu Yang   +3 more
doaj   +1 more source

Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain. [PDF]

PLoS ONE, 2016
PCSK9 is a secreted ligand and negative post-translational regulator of low-density lipoprotein receptor (LDLR) in hepatocytes. Gain-of-function (GOF) or loss-of-function (LOF) mutations in PCSK9 are directly correlated with high or low plasma LDL ...
Steve Poirier, Hocine Ait Hamouda, Louis Villeneuve, Annie Demers, Gaétan Mayer   +4 more
doaj   +1 more source

Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly [PDF]

, 2007
BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) post-transcriptionally degrades the low density lipoprotein receptors (LDLR). However, it is unknown whether PCSK9 acts directly on the LDLR or if PCSK9 activates another protein that in ...
Berge, Knut Erik, Cameron, Jamie, Holla, Øystein L, Leren, Trond P, Ranheim, Trine   +4 more
core   +4 more sources

Indication‐Specific Dosing and Dose‐Evaluation Strategies in New Indications for Non‐Oncology Monoclonal Antibodies

The Journal of Clinical Pharmacology, EarlyView.
Abstract Compared to traditional small molecule drugs, monoclonal antibodies (mAbs) often display more complex pharmacokinetic (PK) and pharmacodynamic (PD) properties that may be impacted by disease‐specific factors. For mAbs in non‐oncology indications, where the same drug might be used for conditions involving different organ systems and/or having ...
Sherouk M. Tawfik, Fei Tang
wiley   +1 more source

PCSK9 Inhibitor Use and Outcomes Using Concomitant Lipid-Lowering Therapies in the Veterans Health Administration

American Journal of Medicine Open, 2023
Background: Real-world data on use of PCSK9 inhibitors (PCSK9-Is), with or without statins and/or ezetimibe, and associated outcomes, can inform more effective prescribing.
Jessica Eloso, Asma Awad, Xinhua Zhao, Francesca E. Cunningham, Rongping Zhang, Diane Dong, Cathy Kelley, Peter A. Glassman, Sherrie L. Aspinall   +8 more
doaj  

Associations Between Lipids and Lipid‐Lowering Drug Target Genes and Osteomyelitis: A Mendelian Randomization Analysis

Medicine Advances, EarlyView.
In this study, we identified several SNPs in PCSK9 as genetic tools to comprehensively assess the influential role of PCSK9 in CHD, CRP, and osteomyelitis. PCSK9 is associated with a lower risk of osteomyelitis, and PCSK9 is also associated with a reduction in CRP concentrations. Our study supports the notion that WC may be a potential mediator between
Zhiyi Zhou, Zhehan Yang, Junpan Chen, Minghao Wen, Jiayuan Lei, Wanzhe Liao, Yahan Li, Linghui Liu, Ziyuan Lu   +8 more
wiley   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders

Frontiers in Neuroscience, 2020
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has long been studied in the liver due to its regulation of plasma low-density lipoprotein cholesterol (LDL-C) and its causal role in familial hypercholesterolemia. Although PCSK9 was first discovered
Emma M. O’Connell, Falk W. Lohoff
doaj   +1 more source

Clinical exome performance for reporting secondary genetic findings. [PDF]

, 2014
BACKGROUND : Reporting clinically actionable incidental genetic findings in the course of clinical exome testing is recommended by the American College of Medical Genet- ics and Genomics (ACMG).
Clark, P, Fortina, Paolo, Kricka, Lj, Londin, E, Park, J. Y., Park, Jy, Sponziello, Marialuisa   +6 more
core   +1 more source

Downregulation of forkhead box O1 (FOXO1) acetylation ameliorates cognitive dysfunction by inhibiting endoplasmic reticulum stress‐regulated neuronal apoptosis in APP/PS1 transgenic mice

Neuroprotection, EarlyView.
Downregulation of the expression of silent information regulator sirtuin 1 (SIRT1) exacerbates neuronal degeneration and loss by activating forkhead box O1 (FOXO1) acetylation and promoting endoplasmic reticulum stress (ERSA)‐mediated apoptosis in aging.
Nan Zhang, Zongyuan Zhao, Xiaoxiao Chen, Hanbing Yao, Min Zhu, Shuqing Ma, Hui Wang, Xianghong Yin, Ying Zhou, Chenfei Zheng, Jianmin Li, Jingye Pan, Kaicheng Wang, Bin Yang, Yunting Wang, Junming Fan, Yongsheng Gong, Rong Liu, Jing Zeng, Xiaofang Fan, Yangping Shentu   +20 more
wiley   +1 more source